درباره این اپیزود

انگلیسی

جستجوی اپیزودهای گذشته

اپیزودهای قبلی Dishing The Science with Dr. Sue را جستجو کن.

قسمت های دیگر در این پادکست

Two out of three people with type 2 diabetes have 'fatty liver disease' (now called MASH/MASLD).  Should everyone with prediabetes or type 2 diabetes be screened? Find out what the brand new Diabetes Canada Guidelines say here! Learn more: https://drsue.ca/2025/09/does-everyone-with-type-…
Obesity expert groups around the world have created guidance documents to reframe the diagnosis and assessment of obesity, to look beyond BMI, and embracing weight-related health issues, which differ in their approaches. Today I'm talking about how we can distill these down into one very simpl…
While we now have several injectable GLP-1s based treatments for weight management around the world [liraglutide (Saxenda), semaglutide (Wegovy), tirzepatide (Zepbound/Mounjaro)], there are no GLP-1s currently available in a pill format for obesity treatment. But that is likely soon to change, back…
Can GLP-1 medications cause altered skin sensations? Find out what we know here. Learn more: https://drsue.ca/2025/10/can-glp-1-medications-cause-funky-skin-sensations-dysesthesia/ Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audi…
Improving quality of life is a central goal in successful weight management.  Do weight loss medications improve quality of life? Are there situations where quality of life could get worse, rather than better?  Learn more: https://drsue.ca/2025/09/do-weight-management-medications-improve-quality-of…
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به Dr. Sue Pedersen است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.